Will a cheaper diabetes pill match the original?

NCT ID NCT07763964

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial asks whether a generic extended-release tablet containing sitagliptin and metformin works the same as the brand-name version (Janumet XR) in healthy adults. Each participant takes a single dose of both medications at different times, and blood tests compare how the body absorbs them. The goal is to confirm the generic is bioequivalent, meaning it delivers the same amount of drug into the bloodstream.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
sitagliptin/metformin
What this could lead to
If the generic tablet proves equivalent, it could offer a more affordable option for managing type 2 diabetes.
What could go wrong
This is a small, early-stage bioequivalence study in healthy volunteers, not a test of long-term safety or effectiveness in patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIOEQUIVALANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Axis Clinicals Latina, S.A. de C.V.

    Mexico City, 07870, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.